Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ProMetic Life Sciences -- Ignore unavailable to you. Want to Upgrade?

To: Leo Fisher who wrote (94)	5/8/2017 3:41:42 PM
From: axial	Respond to of 250

Hi Leo - Prometic has a large basket of promising therapeutics (see next post). Of them all, plasminogen is closest to approval. Meaning production — and revenue. The problem, of course, is the huge cash outlay required to bring other candidates to revenue-producing status with ~668,690,000 shares already outstanding. Right or wrong, Bloom Burton's still-running short attack has diminished market confidence, and can be expected to continue for many months. There's possible help from a few sources: [1] Partnerships [2] Receive and sell Pediatric Priority Review Voucher (est $100 million +) [3] More distributions/dilution [3] Longer-term, rights offering For a junior, there's nothing unusual about this cash crunch. The promise is exciting but near-term gain seems unlikely. Jim